TOP HEADLINES

Featured Story

Novartis combo therapy for COPD shows promise in clinical trials, awaits FDA approval

Novartis announced that its investigational combination indacaterol/glycopyrronium bromide therapy for COPD performed better than its constituent components in a Phase III clinical trial.

Data-gathering insulin pen maker Companion pulls in Series B led by Eli Lilly

Companion Medical, a California startup with a Bluetooth-enabled insulin pen and smartphone app, pulled in Series B financing this week, led by Big Pharma player Eli Lilly. Though the amount was undisclosed, the move marks a step forward for Lilly into the world of drug delivery technology, for which the company is currently building an R&D center in Cambridge, MA.

Pacira's liposomal-encased bupivacaine gets positive reviews at breast cancer conference

Pacira's liposomal-encased bupivacaine medication was touted at the annual Miami Breast Cancer Conference as an effective postoperative pain reliever following breast removal or reconstruction.

Nanoparticles tagged with amino acids help diagnose glioblastoma to someday target drugs

Researchers in Japan have published a study in the journal Science and Technology of Advanced Materials demonstrating greater potential for nanoparticles that can both carry drugs and act as imaging targets to diagnose malignant tumors in the brain.

FDA approves long-acting formulation of J&J schizophrenia med

The FDA gave the green light to Johnson & Johnson's Invega Trinza, which is injected four times a year, making it the longest-acting schizophrenia drug on the market.

MORE NEWS

From Our Sister Sites

FierceMedicalDevices

Zimmer will close its Carlsbad, CA, dental headquarters following its looming $13 billion merger with Biomet, resulting an unspecified number of layoffs. The plant closure will occur in 12 months, say internal company emails sent to both companies' employees that were obtained by FierceMedicalDevices.

FiercePharma

Johnson & Johnson and AbbVie's Imbruvica has already shown in one Phase III study that it can extend progression-free survival in patients with previously treated chronic lymphocytic leukemia. But now, it's done it again--and convincingly so.